ArticlemSphere2019
A Cohort Study of the Impact of Carbapenem-Resistant
Article in mSphere, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.
- Prognostic factors of sepsis: a systematic review and meta-analysis.BMC infectious diseases · 2025Pooled it
- Construction of a Risk Prediction Model for Subsequent Bloodstream Infection in Intestinal Carriers of Carbapenem-Resistant Enterobacteriaceae: A Retrospective Study in Hematology Department and Intensive Care Unit.Infection and drug resistance · 2021Trial
- Beyond β-Lactams: Defining the Role of Eravacycline in Multidrug-Resistant and Metallo-β-Lactamase-Producing Infections.Antibiotics (Basel, Switzerland) · 2026Review
- Recurrence, Readmission, and Key Mortality Predictors in Patients with Carbapenem-Resistant Enterobacterales Infections.Diagnostics (Basel, Switzerland) · 2025Article
- Biorecognition-Based Nanodiagnostics: Maltotriose-Functionalized Magnetic Nanoparticles for Targeted Magnetic Resonance Imaging of Bacterial Infections.Bioengineering (Basel, Switzerland) · 2025Article
- Review
- Risk factors, and outcomes of patients with carbapenem-resistantFrontiers in cellular and infection microbiology · 2025Article
- Antimicrobial and Anti-Biofilm Activity of Dichlorophen-Functionalized Gold Nanoparticles Against Carbapenem-ResistantInternational journal of nanomedicine · 2025Article
- Temporal Shifts in Etiological Agents and Trends in Antimicrobial Resistance of Bloodstream Infection in Southwest China from 2016 to 2023.Infection and drug resistance · 2025Article
- Dynamic cytokine profiles of bloodstream infection caused by Klebsiella pneumoniae in China.Annals of clinical microbiology and antimicrobials · 2024Article
- High prevalence of carbapenem-resistantHeliyon · 2024Article
- Carbapenem-resistant Enterobacterales sepsis following endoscopic retrograde cholangiopancreatography: risk factors for 30-day all-cause mortality and the development of a nomogram based on a retrospective cohort.Antimicrobial resistance and infection control · 2024Article
- Lower Urinary Tract Inflammation and Infection: Key Microbiological and Immunological Aspects.Journal of clinical medicine · 2024Review
- Production of OXA-48 carbapenemase acts as an independent risk factor for poor outcome in Klebsiella pneumoniae infection.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2023Article
- Visualizing Bacterial Infections With Novel Targeted Molecular Imaging Approaches.The Journal of infectious diseases · 2023Article
- Epidemiology and mortality outcome of carbapenem- and colistin-resistantIJID regions · 2023Article
- Low-molecular-weight heparin therapy reduces 28-day mortality in patients with sepsis-3 by improving inflammation and coagulopathy.Frontiers in medicine · 2023Article
- Treatments and Predictors of Mortality for Carbapenem-Resistant Gram-Negative Bacilli Infections in Malaysia: A Retrospective Cohort Study.Tropical medicine and infectious disease · 2022Article
- Risk factors for carbapenem-resistant Enterobacterales infection among hospitalized patients with previous colonization.Journal of clinical laboratory analysis · 2022Article
- Genomic Epidemiology of Carbapenemase-Producing and Colistin-ResistantAntimicrobial agents and chemotherapy · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The objective of this study is to evaluate the impact of carbapenem-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.